If you want to distinguish your goods, services or both from those of another company, you may need a trademark or trade name. Find out what they are, what their registration procedure is and what it involves.
Information on the deadlines for filing applications for transformation of European Union trademarks into Spanish national trademarks. See more
If you have a new device, product or procedure that solves a technical problem or has a practical advantage, there are different ways to protect it in Spain and other countries. Find out how.
Does your innovation lie in the aesthetics, ornamentation or appearance of your product? Protect it through industrial design. Find out what rights registration confers and how to proceed.
Patents published worldwide are a valuable source of scientific, technical and commercial information.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
If you are an entrepreneur or a company and you want to boost and improve the profitability of your business by adequately protecting the intangible assets of your organisation, in this space you will find what you need.
202
results.
Updated on
09/05/2025 [06:51:00]
Results 50 to 75 of 202
Absstract of: CN119912435A
本发明公开了一种用于肺部疾病治疗的纳米颗粒及其制备方法与应用。本发明所提供的用于肺部疾病治疗的纳米颗粒包括纳米颗粒载体和核酸分子；所述纳米颗粒载体，其原料包括所述TM2和DOPE，两者的摩尔比为1:2。本发明提供的包载核酸的纳米颗粒能够高效地将核酸分子递送至肺部，下调致病蛋白表达；能够显著增加药物在肺部的沉积，有效保证了给药以后的效果，同时具有给药方式简便，无创伤，安全性高等优点，是一种具有高创新性的高效肺部沉积的一种方式，在肺部相关疾病治疗方面具有很好的应用前景。
Absstract of: CN119909038A
本发明属于药品技术领域，具体涉及一种蜂皇浆冻干粉的包衣方法及其产品、应用、养肝胶囊及其制备方法。所述蜂皇浆冻干粉的包衣方法，包括以下步骤：S1、将包衣材料溶解于溶剂中，得包衣液：S2、采用包衣液对蜂皇浆冻干粉进行包衣，得包衣蜂皇浆冻干粉；所述包衣材料包括羟丙甲纤维素、改性麦芽糊精和异麦芽酮糖醇。采用本发明提供的包衣蜂皇浆冻干粉制备得到的养肝胶囊在阴凉、常温和加速条件下的水分含量均合格，而且避免了蜂皇浆冻干粉含量的严重下降。
Absstract of: JP2024094323A
To provide innovative drugs, medical products and imaging agents.SOLUTION: Provided is a method of imaging a subject, comprising: (i) administering to the subject an imaging agent having a plurality of nanostructures, each of the nanostructures comprising a multi-armed PEG and one or more additives that interact with the multi-armed PEG, and the multi-armed PEG of each of the plurality of nanostructures is sufficient to provide a nuclear magnetic resonance image when scanned in step (ii); (ii) following step (i), performing an imaging scan of the subject, the imaging scan being a nuclear magnetic resonance scan; and (iii) providing a nuclear magnetic resonance image of the multi-armed PEG of the plurality of nanostructures.
Absstract of: CN119912351A
本发明涉及一种脂质化合物及其组合物。具体而言，本发明涉及式(I)的脂质化合物，包含其的脂质纳米颗粒，及其制备方法和在药物递送中的用途。#imgabs0#
Absstract of: CN119912352A
本发明提供了一种氟代脂质体及其制备方法和应用。这一系列结构新颖的高度氟化的可离子化的脂质分子制备方法具有合成简单、产率高的优点。本发明还提供了包含氟代可离子化脂质或复合离子化脂质的LNP，所述LNP粒径分散性好，对于核酸的包封率高，生物体内毒性较低，可以高效的递送核酸药物使其具有更好的进细胞效率、核酸的表达效率，并具有脾脏靶向性，在免疫治疗中具有重大的应用前景。
Absstract of: CN119909037A
本发明公开了一种负载胰岛素的复合纳米颗粒及其制备方法和应用，复合纳米颗粒具有核壳结构，核为L‑缬氨酸修饰的壳聚糖与胰岛素自组装形成的聚电解质络合物，壳为阴离子多糖；或者复合纳米颗粒具有多层核壳结构，核为苯硼酸修饰的明胶与胰岛素自组装形成的聚电解质络合物，外面形成两层壳：L‑缬氨酸修饰的壳聚糖、褐藻糖胶。本发明可作糖尿病治疗的口服给药和注射给药。
Absstract of: CN119909035A
本发明公开了一种用于黑色素瘤靶向成像和光热治疗的自组装纳米颗粒，旨在解决现有光热治疗黑色素瘤方法中靶向性不强、光热效率低以及生物相容性差的问题。本发明设计了一种基于特定多肽(SA‑7)、芳香氨基酸(FF)和卟啉(TPP)的自组装纳米颗粒。通过自组装形成的纳米颗粒能够高效靶向黑色素瘤细胞，在638nm激光照射下产生强效的光热效应。同时，该纳米颗粒具有良好的生物相容性和代谢性能，可用于黑色素瘤的精准成像和治疗。
Absstract of: CN119424347A
The invention discloses an application of naringenin nanoparticles in preparation of a ceftiofur long-acting preparation. The invention discloses naringenin (5, 7-dihydroxy-2 (4-hydroxyphenyl) chroman-4-ketone), which is a flavonoid substance. The naringenin nanoparticles are prepared, the naringenin nanoparticles are mixed with the ceftiofur for combined use, and it is found that the naringenin can effectively intervene in the pharmacokinetic process of the ceftiofur and significantly prolong the in-vivo half-life period of the ceftiofur, so that the in-vivo action time of the ceftiofur is prolonged, and the curative effect of the ceftiofur is improved. Moreover, the application method is simple, easy to operate, low in cost and suitable for large-scale popularization.
Absstract of: WO2025088570A1
A compound having the following structure of Formula (I) or a stereoisomer of the compound, tautomer of the compound, pharmaceutically acceptable salt thereof, wherein A1, A2, A3, R1a, R1b, R2a, R2b, m1, m2, m3, and X are as defined herein. Pharmaceutical composition comprising the compounds, and their use in methods of treating diseases are also described.
Absstract of: WO2025088346A1
Provided is lipid nanoparticle functionalised with a glycopolymer. The glycopolymer comprises at least four carbohydrate units, wherein each carbohydrate unit is independently selected from a monosaccharide, a disaccharide and an oligosaccharide. The lipid nanoparticle can be used for inducing an immune response in a subject.
Absstract of: US2025135007A1
Disclosed herein are compositions comprising sterol-amino-phosphate compounds and methods of making and use thereof. Also disclosed herein are methods of making and methods of use of the compounds, compositions, and/or lipid particles disclosed herein. For example, the compounds and compositions are useful for treating a disease or disorder in humans and in animals. In some examples, the subject is a human male and the disease or disorder comprises male infertility.
Absstract of: US2025134925A1
According to an example aspect of the present invention, there is provided isolated bioactive mitochondria coated with a layer of Metal Organic Framework (MOF) and a method for intracellular delivery and release of said coated bioactive mitochondria in cells. The invention also provides a method for maintaining bioactivity and for increasing storage time of bioactive mitochondria by using MOF encapsulation.
Absstract of: US2025136985A1
Disclosed herein is a pharmaceutically effective composition comprising at least one of a phosphorothioate (PS)-based anti-miR-141-3p oligonucleotide; a peptide nucleic acid (PNA)-based anti-miR-141-3p oligonucleotide; and/or a gamma-peptide nucleic acid (γ-PNA)-based anti-miR-141-3p oligonucleotide; where at least one of the foregoing oligonucleotides is encapsulated in a biocompatible nanoparticle.
Absstract of: US2025135050A1
Iodide nanoparticles are provided. The nanoparticles can be potassium iodide (KI) nanoparticles, and can be formed of, a radioisotope, preferably 131I or 125I. The nanoparticles can include a coating that can increase the half-life of the particles, serve as a platform for attachment or entrapment of targeting moieties and/or additional active agents, or a combination thereof. Methods of use are also provided. For example, a method of treating a subject for cancer can including sensitizing the subject to radiation therapy by administrating the iodide nanoparticles to the subject in combination with one or more doses of radiation therapy. Methods of treating or imaging a subject can also include administering the subject an effective amount iodide nanoparticles, without the nanoparticles serving as radiosensitizer. In such methods, the nanoparticles typically include a radioisotope or an anticancer active agent, for example 131I, 125I, 124I, or 123I, or a chemotherapeutic agent.
Absstract of: WO2025088192A1
The present invention provides for inventive means and methods for the coupling of di(alkyl)amines to polypeptides or peptides capable of forming a random coil conformation. The present invention further provides inventive compounds produced by the herein detailed methods, wherein said compounds are characterized by formula (I): A-B-bC-D. Said compounds comprise a polypeptide/peptide capable of forming a random coil conformation, an N-terminal protecting group, a di(alkyl)amino group, and optionally a linker. Furthermore, the present invention provides lipid nanoparticles comprising said compounds characterized by formula (I) as well as means and methods for the production of said lipid nanoparticles. Formulations comprising the inventive compounds and/or the lipid nanoparticles of the present invention are also provided. Further, the present invention also relates to uses of the inventive compounds, the lipid nanoparticles, and/or the formulations disclosed herein.
Absstract of: US2025134989A1
The present invention relates to a novel vaccine composition for coronavirus infection-19 comprising a polymer-based mRNA carrier. Specifically, the present invention provides a vaccine composition comprising an mRNA carrier using a novel polymer capable of delivering a negatively charged genetic material such as mRNA, and the vaccine composition has excellent effects of enhanced in vivo immune activity such as high antibody formation ability and increased interferon-gamma production.
Absstract of: US2025134986A1
Provided herein are, inter alia, compositions or formulations comprising a nucleic acid (e.g. a RNA molecule) encapsulated in a lipid nanoparticle (LNP) and their uses.
Absstract of: US2025134994A1
The present disclosure relates to lipid-based delivery vehicles for mRNA vaccines, which include a lysophosphatidylcholine (LPC) compound for enhancing vaccine immunogenicity. The present disclosure also relates to methods for use of the mRNA vaccines.
Absstract of: US2025134969A1
A biosynthetic hemostat includes a plurality of biocompatible flexible nanoparticles wherein each nanoparticle includes a shell that defines an outer surface of the nanoparticle and a core, which is loaded with thrombin, and a plurality of von Willebrand factor-binding peptides (VBPs) and collagen-binding peptides (CBPs) that are linked to the shell and extend from the outer surface.
Absstract of: US2025135028A1
The present disclosure provides copolymers and glycopeptide antibiotic-loaded polymeric nanoparticles (PNPs) comprising the copolymers as well as charge neutral polymers for targeted and sustained delivery of glycopeptide antibiotics to treat bacterial infections, including but not limited to biofilm bacterial infections. The copolymers are block, alternate, or random copolymers comprising x units of the formulaand y units of the formulawherein Z is an organic moiety, R and R′ are each independently selected from the group consisting of hydrogen and C1-C18 alkyl, each of x and y is an integer of 1 or greater, the sum of x and y is an integer from about 40 to about 714, and y is from about 10% to about 90% of the sum of x and y.
Absstract of: US2025135017A1
Linker-drug compounds and antibody-drug conjugates that bind to human oncology targets are disclosed. The linker-drug compounds and antibody-drug conjugates comprise a splicing modulator drug moiety. The disclosure further relates to methods and compositions for use in the treatment of neoplastic disorders by administering the antibody-drug conjugates provided herein.
Absstract of: US2025135027A1
Disclosed herein are cell-targeting complexes that are coated on the surface with target specific antibodies for induction of biological stimulus in target cells/tissue/organs. In some embodiments, the cell-targeting complex involves nonnucleated (e.g. platelets, red blood cells (RBC)) or enucleated cells that have been thiolated, streptavidinylated, and then coated with biotinylated antibodies. In some embodiments, the cell-targeting complex involves multilayer alginate hydrogel beads that have been coated with polyanionic proteins using a polycation, which is then thiolated, streptavidinylated, and then coated with biotinylated antibodies.
Absstract of: WO2025091046A1
Provided are compositions that include compositions of galactosyl -conjugated lipid nanoparticles (LNPs) encapsulating one or more active agents. In some embodiments, the galactosyl- conjugated LNPs have a lipid component having D-Lin~MC3-DMA, ALC-0315 and. SM-102, cholesterol, DSPC and DOPE, and DMG-2000-PEG. In some embodiments, the GalNAc-conjugated LNP has one or more galactosyl moieties bioconjugated to cholesterol present with a lipid component of the GalNAc -conjugated LNP. Also provided are methods for treating and/or preventing diseases, disorders, and/or conditions associated, with undesirable PCSK9 gene expression, optionally a cardiovascular disease, disorder, or condition, including but not limited, to atherosclerosis and/or thrombosis, and sepsis, septic shock, cytokine storm, or sequelae thereof.
Absstract of: WO2025090023A1
There is provided a compound comprising a structure represented by general formula (1) or an ionized form thereof for preparing lipid nanoparticles encapsulating a therapeutic, prophylactic and/or biological agent: wherein R5 and each R6 are independently H, optionally substituted alkyl, optionally substituted alkenyl, or optionally substituted alkynyl; R3, and each R7 are independently optionally substituted alkylene, optionally substituted alkenylene, or optionally substituted alkynylene; n is from 0 to 100; l and m are each independently 0 or 1; each A is independently selected from H, aliphatic alcohol, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, an epoxy ring- opening product and/or derivatives thereof; and B is R1R2N- or R23O- where R1 and R2 are each independently H, or a hydrophobic tail with the proviso that both of R1 and R2 are not H at the same 116 time; and where R23 is optionally substituted alkyl, optionally substituted alkenyl, or optionally substituted alkynyl.
Nº publicación: WO2025090968A1 01/05/2025
Applicant:
SLINGSHOT BIOSCIENCES INC [US]
SLINGSHOT BIOSCIENCES, INC
Absstract of: WO2025090968A1
Bead-in-particles formats and their use in cytometric applications are described. In one aspect, the disclosure provides a bead-in-particle comprising an outer hydrogel body and an inner hydrogel bead. As described herein, the bead-in-particle is selectively tuned to have at least one morphological property substantially similar to subcellular macrostructures of interest present in a target cell. In one aspect of the disclosure, the bead-in-particle are used as a calibration reagent for the detection of a target cell in a sample, such as by image-based flow cytometry.
BOPI
Electronic site
